MimiVax Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$5.78M
- Investors
-
7
MimiVax General Information
Description
Developer of immunotherapeutic vaccines and targeted therapies intended to control tumor growth and recurrence. The company's vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers, enabling healthcare providers to disrupt cancer, cure patients, and increase patient survival rates.
Contact Information
Website
www.mimivax.comCorporate Office
- Elm & Carlton Streets
- Buffalo, NY 14263
- United States
Corporate Office
- Elm & Carlton Streets
- Buffalo, NY 14263
- United States
MimiVax Timeline
MimiVax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Debt - General | 12-Jul-2024 | $5.78M | Completed | Generating Revenue | ||
| 8. Later Stage VC | 09-Jan-2024 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 10-Dec-2021 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 24-Jun-2020 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC | 02-Aug-2019 | Cancelled | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC | Completed | Clinical Trials - Phase 1 | ||||
| 3. Early Stage VC (Series A) | 25-Aug-2015 | Completed | Startup | |||
| 2. Grant | 01-Mar-2015 | $2M | $450K | Completed | Startup | |
| 1. Seed Round | 01-Jan-2012 | $450K | $450K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
MimiVax Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MimiVax Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MimiVax Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MEDA Angels | Angel Group | Minority | ||
| The Brain Tumor Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| The Sontag Foundation | Limited Partner | Minority | ||
| Angel (individual) | Minority | |||
| Varia Ventures | Venture Capital | Minority |
MimiVax FAQs
-
When was MimiVax founded?
MimiVax was founded in 2011.
-
Where is MimiVax headquartered?
MimiVax is headquartered in Buffalo, NY.
-
What is the size of MimiVax?
MimiVax has 3 total employees.
-
What industry is MimiVax in?
MimiVax’s primary industry is Drug Discovery.
-
Is MimiVax a private or public company?
MimiVax is a Private company.
-
What is MimiVax’s current revenue?
The current revenue for MimiVax is .
-
How much funding has MimiVax raised over time?
MimiVax has raised $20.8M.
-
Who are MimiVax’s investors?
MEDA Angels, The Brain Tumor Investment Fund, The Sontag Foundation, , and Varia Ventures are 5 of 7 investors who have invested in MimiVax.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
